Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
FAIL · Does not pass the screen
126.63 USD
At the last full screen 2026-09-02
Screened 2026-09-02 · the tape above runs as of 17:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Insmed Inc holds its Markdown at $126.63. The statistical read favours the sellers, held for 19 days.
As held on the ledger · 2026-09-02
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 19 days
Price at the screen
$126.63
Valuation
N/A trailing · 157.85 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.79
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
25.91%
Below 33%
Interest-bearing debt is just 25.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
40.61%
Below 33%
Interest-bearing cash and securities are 40.6% of assets, above the one-third limit.
Fail
Receivables
28.76%
Below 49%
Money owed to the company is 28.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-02 screen. The gold marker is the market price at the same screen. The price runs 15.0% above the base estimate.
Third-party analyst targets: 22 covering, consensus Strong Buy. The average target sits +56% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare disease biotech priced for perfection
A patient in Japan finally clearing a stubborn lung infection marks real progress for families who had few options before. Insmed is delivering that progress, with revenue up 230 percent as its lead therapy gains ground across the US, Europe and Japan.
Yet the shares sit 6 percent above our fair value at an 814 times forward multiple while margins sit at minus 144 percent and return on equity at minus 294 percent. Narrow moat and strong buy analyst targets do not change the fact that current pricing leaves almost no margin of safety.
Execution risk in rare disease trials, regulatory delays abroad and the need to turn rapid top line growth into actual profits remain the central concerns. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
INSM trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-02Markup · changed$123.74+18.8%Entry 5
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197.
2026-08-02Markdown · changed$104.13+6.4%Entry 4
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 6.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197.
2026-07-18Distribution$97.85+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (21 analysts) rates it strong buy, with a mean price target of $197.
2026-07-03Distribution$97.85+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$97.85Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
